Browsing Tag
UX143
2 posts
Ultragenyx Pharmaceutical faces shareholder litigation risks after Orbit study update triggers stock plunge
Ultragenyx faces legal probe and investor scrutiny after a 25% stock drop tied to delayed Phase 3 Orbit study data for UX143. Learn what analysts expect next.
Ultragenyx stock plummets 25% after Phase 3 OI trial continues without early stop
Ultragenyx stock plunged 25% as the UX143 Phase 3 trial for osteogenesis imperfecta proceeds without early stop. Find out what this means for investors.